FDG PET/CT for Lung Cancer

Overseen By Daniel Pryma, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Abramson Cancer Center of the University of Pennsylvania

Disqualifiers: Mental disability, Children, Prisoners, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Approved in 6 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

30 Participants Needed

Trial Summary

What is the purpose of this trial?

Prospective study of the effects of image acquisition and reconstruction parameters on accuracy of FDG PET/CT mediastinal nodal staging in NSCLC

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment FDG PET/CT for lung cancer?

FDG PET/CT is effective in managing lung cancer by providing detailed images that help in diagnosing the disease, planning treatment, and predicting how well a patient might respond to therapy. It combines two types of scans to give a clearer picture of the cancer's location and spread, which is crucial for effective treatment planning. ^{1 2 3 4 5}

Is FDG PET/CT safe for use in humans?

FDG PET/CT is generally considered safe for use in humans as it is a noninvasive imaging technique used widely in cancer diagnosis and management. While it is important to be aware of potential misinterpretations due to therapy-related changes, there are no specific safety concerns directly associated with the FDG PET/CT procedure itself. ^{6 7 8 9 10}

How does FDG PET/CT differ from other treatments for lung cancer?

FDG PET/CT is unique because it combines metabolic and anatomical imaging to help diagnose, stage, and manage lung cancer more precisely. Unlike traditional imaging methods, it uses a special tracer to highlight areas of increased glucose metabolism, which is common in cancer cells, allowing for better detection and treatment planning. ^{1 3 11 12 13}

Research Team

Daniel Pryma, MD

Principal Investigator

Abramson Cancer Center at Penn Medicine

Eligibility Criteria

This trial is for adults over 18 with a diagnosis of non-small cell lung cancer (NSCLC) who need an FDG PET/CT scan as part of their usual care. They must understand the study's research nature and agree to it in writing. It's not for those who can't handle extra imaging time, economically disadvantaged individuals, children, neonates, prisoners, or mentally disabled persons.

Inclusion Criteria

I have NSCLC and am scheduled for a PET/CT scan.

Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion Criteria

I am not a child, fetus, neonate, or prisoner.

Inability to tolerate additional imaging time in the opinion of the investigator or treating physician

Individuals who are mentally disabled

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

PET Imaging

Participants undergo FDG PET/CT imaging to assess mediastinal nodal staging in NSCLC

1 week

Follow-up

Participants are monitored for safety and effectiveness after imaging

4 weeks

Treatment Details

Interventions

• FDG PET/CT

Trial Overview The study is looking at how different ways of taking pictures and processing them affect the accuracy of FDG PET/CT scans used to figure out if NSCLC has spread to lymph nodes in the chest area. This is a forward-looking study that tracks participants over time.

Participant Groups

Group I: PET imaging Experimental Treatment 1 Intervention

PET imaging

Who Is Running the Clinical Trial?

Abramson Cancer Center of the University of Pennsylvania

Lead Sponsor

Trials

360

Recruited

108,000+

Abramson Cancer Center at Penn Medicine

Lead Sponsor

Trials

425

Recruited

464,000+

Findings from Research

(18)F-FDG PET/CT is a valuable imaging tool that combines metabolic and anatomical information, enhancing the management of lung cancer patients throughout various stages of care.

The review highlights its effectiveness in critical areas such as diagnosis, staging, therapy planning, and assessing treatment responses, making it essential for improving patient outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Present and future roles of FDG-PET/CT imaging in the management of lung cancer. Kitajima, K., Doi, H., Kanda, T., et al.[2018]

FDG-PET/CT imaging has significantly improved the diagnosis and management of lung cancer, aiding in the development of therapeutic biomarkers and predicting patient responses and long-term survival.

The review highlights ongoing advancements in novel tracers and optimized procedures for PET/CT, suggesting a promising future for enhancing the effectiveness of lung cancer imaging and treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Progress and future prospective of FDG-PET/CT imaging combined with optimized procedures in lung cancer: toward precision medicine. Guo, H., Xu, K., Duan, G., et al.[2022]

FDG-PET is an effective noninvasive imaging technique for detecting and staging non-small-cell lung cancer, helping to reduce the need for invasive histopathological procedures.

While FDG-PET is sensitive, it is not tumor-specific and can lead to false positives due to accumulation in nonmalignant conditions; combining it with CT imaging improves staging accuracy for lung cancer patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

State-of-the-Art FDG-PET imaging of lung cancer. Gilman, MD., Aquino, SL.[2019]

Positron emission tomography (PET) using the radiopharmaceutical 18F-2-deoxy-D-glucose (FDG) is a valuable noninvasive tool that enhances the evaluation of lung cancer beyond traditional imaging methods like CT and MRI.

FDG-PET is effective for various applications in lung cancer management, including detecting tumors, staging the disease, monitoring for recurrence, and assessing patient prognosis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Positron emission tomography imaging in lung cancer. Patz, EF., Erasmus, JJ.[2019]

References

1. Japan pubmed.ncbi.nlm.nih.gov

Present and future roles of FDG-PET/CT imaging in the management of lung cancer. [2018]

2. India pubmed.ncbi.nlm.nih.gov

Positron emission tomography in the management of lung cancer. [2021]

3. Japan pubmed.ncbi.nlm.nih.gov

Progress and future prospective of FDG-PET/CT imaging combined with optimized procedures in lung cancer: toward precision medicine. [2022]

4. England pubmed.ncbi.nlm.nih.gov

Guidelines for the role of FDG-PET/CT in lung cancer management. [2016]

5. Switzerland pubmed.ncbi.nlm.nih.gov

FDG-PET/CT in lung cancer: an update. [2019]

6. United States pubmed.ncbi.nlm.nih.gov

State-of-the-Art FDG-PET imaging of lung cancer. [2019]

7. United States pubmed.ncbi.nlm.nih.gov

Side Effects of Oncologic Treatment in the Chest: Manifestations at FDG PET/CT. [2021]

8. United States pubmed.ncbi.nlm.nih.gov

Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. [2016]

9. United States pubmed.ncbi.nlm.nih.gov

Thoracic FDG PET: state of the art. [2016]

10. Ireland pubmed.ncbi.nlm.nih.gov

Value of FDG PET in the management of NSCLC. [2016]

11. China pubmed.ncbi.nlm.nih.gov

[Value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in early diagnosis of lung cancer]. [2016]

12. United States pubmed.ncbi.nlm.nih.gov

Positron emission tomography imaging in lung cancer. [2019]

13. Switzerland pubmed.ncbi.nlm.nih.gov

The future in diagnosis and staging of lung cancer: positron emission tomography. [2016]